Use of an SGLT-2 inhibitor was associated with a lower incidence of heart failure in patients with CKD, compared with placebo: RR 0.67 (95% CI 0.61–0.75; P < 0.001) (Fig. 2 and Table 3). The gene discussed is SLC5A2; the disease is heart failure.